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Abstract
To report outcome (freedom from local progression [FFLP], overall survival [OS] and
toxicity) after stereotactic, palliative or highly conformal fractionated (>12) radiother-
apy (SBRT, Pall-RT, 3DCRT/IMRT) for adrenal metastases in a retrospective multicenter
cohort within the framework of the German Society for Radiation Oncology (DEGRO).
Adrenal metastases treated with SBRT (≤12 fractions, biologically effective dose
[BED10] ≥ 50 Gy), 3DCRT/IMRT (>12 fractions, BED10 ≥ 50 Gy) or Pall-RT
(BED10 < 50 Gy) were eligible for this analysis. In addition to unadjusted FFLP
(Kaplan-Meier/log-rank), we calculated the competing-risk-adjusted local recurrence
rate (CRA-LRR). Three hundred twenty-six patients with 366 metastases were included
by 21 centers (median follow-up: 11.7 months). Treatment was SBRT, 3DCRT/IMRT
and Pall-RT in 260, 27 and 79 cases, respectively. Most frequent primary tumors were
non-small-cell lung cancer (NSCLC; 52.5%), SCLC (16.3%) and melanoma (6.7%).
Unadjusted FFLP was higher after SBRT vs Pall-RT (P = .026) while numerical differ-
ences in CRA-LRR between groups did not reach statistical significance (1-year CRA-
LRR: 13.8%, 17.4% and 27.7%). OS was longer after SBRT vs other groups (P < .05)
and increased in patients with locally controlled metastases in a landmark analysis
(P < .0001). Toxicity was mostly mild; notably, four cases of adrenal insufficiency
occurred, two of which were likely caused by immunotherapy or tumor progression.
Radiotherapy for adrenal metastases was associated with a mild toxicity profile in all
groups and a favorable 1-year CRA-LRR after SBRT or 3DCRT/IMRT. One-year FFLP
was associated with longer OS. Dose-response analyses for the dataset are underway.
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1 | INTRODUCTION
Patients with oligometastatic cancer, which is defined by a limited
number of metastases1,2 may potentially reach long-term freedom of
disease and overall survival (OS). OS for oligometastatic patients
might be prolonged by an effective local treatment in addition to sys-
temic therapy.3-7 For stereotactic body radiation therapy (SBRT), bio-
logically high radiation doses are delivered in a few fractions under
high precision and generally with multidirectional steep dose gradients
and high-precision patient setup.8-12 Image-guided, three-dimensional
conformal radiotherapy or intensity-modulated radiotherapy (IGRT,
3DCRT, IMRT) and/or SBRT can be delivered to metastatic sites as an
individualized treatment. Results of randomized Phase II studies indi-
cate an increased OS in patients who received local treatment using
surgery, radiofrequency ablation, IMRT or SBRT.3,5-7 Larger, well-
powered studies are ongoing in the oligometastatic setting with vary-
ing cutoff values for the total number of metastases, ranging from up
to three (NCT03862911) and up to five lesions (NCT02089100). Clini-
cal outcomes of SBRT appear to differ between involved organ sys-
tems: SBRT of lung metastases achieves excellent 1-year local control
What's new?
When added to systemic therapy, does local treatment
reduce recurrence or overall survival (OS) for patients with
limited metastases? In this study, the authors found that, in
patients with adrenal metastases, both stereotactic body
radiotherapy (SBRT) and highly conformal, intensity-
modulated radiotherapy (3DCRT/IMRT) were associated
with a decreased local recurrence rate and a mild toxicity
profile. Local control at 12 months was, in turn, associated
with increased OS.
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(LC)-rates of 90%,13 whereas results appear worse for liver metastases
with 1-year LC rates of 77%.14
Metastases to the adrenal glands can occur in various solid
tumors, especially the lung, breast, gastric and renal cancer.15 Adre-
nal metastases are symptomatic in approximately 4% of affected
patients15 requiring palliative local treatment modalities such as
resection, invasive ablation or radiotherapy (RT), all with the risk of
treatment-related toxicities, potentially compromising quality of life.16-18
However, for isolated adrenal metastases, local therapy can also result in
a long-term freedom of progression.19 Surgical resection of adrenal
metastases in the oligometastatic setting has been described in some
series20,21; however, the evidence is limited and there is no consensus
on the optimal local treatment approach.
SBRT of adrenal metastases has been evaluated by several groups
in mostly monocentric and retrospective cohort studies with promis-
ing results.16,22-33 Larger analyses include a retrospective database
analysis conducted in Asian patients (n = 75) reporting 1-year LC rate
of 83%.34 Furthermore, multiple prospective and retrospective mono-
centric studies were included in a recent meta-analysis conducted by
Chen et al, which reported a pooled 1-year LC rate of 82% with a
strong association of prescribed doses and LC rates.32
We conducted this multicenter database analysis of patients with
adrenal metastases treated with SBRT or fractionated highly confor-
mal RT (3DCRT/IMRT) within the framework of the SBRT database
initiative of the Working Group Radiosurgery and Stereotactic Radio-
therapy of the German Society for Radiation Oncology (DEGRO). Pat-
terns of care and outcomes by means of toxicity, LC and OS are
detailed in this report.
2 | PATIENTS AND METHODS
2.1 | Patient characteristics, data collection and
patterns of care
Data of a retrospective multicenter patient cohort with adrenal metasta-
ses irrespective of the primary cancer were analyzed. The selection crite-
rion for this cohort was at least one adrenal metastasis treated by RT of
any histologically proven solid tumor. For comparison of heterogeneous
dose prescriptions and fractionation schedules, the linear-quadratic
model was used with an assumed α/β of 10 Gy to convert absolute
doses to biologically effective doses (BED10) for each treated lesion.
Due to the multi-institutional, multi-platform and retrospective
nature of the study, different strata based on prescribed dose and
fractionation were defined as follows:
1. SBRT: ≤12 fractions, BED10 ≥ 50 Gy,
2. 3DCRT/IMRT: > 12 fractions, BED10 ≥ 50 Gy, and
3. Palliative RT (Pall-RT): any fractionation using low prescription
doses (BED10 < 50 Gy).
Highly conformal RT planning and delivery approaches were man-
datory in all arms.
2.2 | Follow up, survival- and statistical analysis
Statistical analyzes were performed using R (Version 3.6.3; The R
Foundation for Statistical Computing, Vienna, Austria).35
Progression-free survival (PFS) and OS were calculated by
using the Kaplan-Meier method. PFS was defined as the time from
the end of the RT to any in- or out-of-field disease progression
(according to Response Evaluation Criteria in Solid Tumors: RECIST
1.1). OS was defined as the interval from the end of RT to the day
of death or censoring; survival curves were truncated at 60 months.
Freedom from local progression (FFLP) was defined as the time
from the end of the RT to the radiologically diagnosed local relapse
(in-field and/or penumbra). We also calculated FFLP using the
Kaplan-Meier method (unadjusted FFLP); however, due to the high
number of cases with informative censoring (deaths without local
relapse, that is, competing events), which were also unevenly dis-
tributed between the arms, the unadjusted Kaplan-Meier approach
may be characterized by larger inaccuracy.36,37 Therefore, we used
a cumulative incidence function to calculate a competing risk-
adjusted local recurrence rate (CRA-LRR) using Gray's test to com-
pare groups.38 The alpha level was set at .05. For the landmark
analysis, we used a 12-months cut point.
2.3 | Toxicity
Acute toxicity (gastrointestinal tract and any other toxicity, including
adrenal insufficiency) of patients was defined as toxicity occurring up
to 90 days post-treatment, late toxicity as occurring after more than
90 days. We recorded toxicity grade 3/4 (Common Terminology
Criteria for Adverse Events [CTCAE] V5.039) and/or any toxicity which
required treatment. Doses to the adrenal glands and organs at risk
(average dose [Dmean] and median dose [D50] to the kidneys; maxi-
mum dose [Dmax] to stomach/duodenum, and Dmean to the liver)
were collected only in case aforementioned toxicity criteria were met.
3 | RESULTS
3.1 | Patient/tumor characteristics and patterns
of care
Data of 326 patients (36.2% female, mean ± SD age 64.8
± 10.5 years) with 366 adrenal metastases treated between 2006 and
2019 were included from 21 German and Swiss centers (13 universi-
ties, 2 public and 6 private centers). The median follow-up interval
was 11.7 (mean: 15.9) months. In case of exclusion of deceased
patients, the median follow-up interval was 15.8 (mean: 20.3) months.
The median number of patients and lesions per institution was 13 and
15, respectively. 260, 27 and 79 adrenal metastases met the criteria
of SBRT, 3DCRT/IMRT and Pall-RT, respectively. Most frequent pri-
mary tumors were non-small-cell lung cancer (52.5%), small-cell lung
cancer (16.3%) and melanoma (6.7%). At the time of RT, the median
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TABLE 1 Patient and tumor characteristics of patients with adrenal metastases included in the database
Patient and tumor characteristics All SBRT
3DCRT
/IMRT Pall-RT
Lesions n 366 260 27 79
Patients n 326 232 26 68
Gender M/F % 63.8/36.2 65.8/34.1 53.8/46.2 63.2/36.8
KPS Median (range), % 90 (50-100) 90 (60-100) 90 (50-100) 90
(50-100)
>80% (%) 47.2 44.8 53.8 52.9
≤80% (%) 39.3 41.4 26.9 36.8
Unknown (%) 13.5 13.8 19.2 10.3
Primary tumor NSCLC, % 52.5 53.4 61.5 45.6
SCLC, % 16.3 14.2 11.5 25
Melanoma, % 6.7 6 3.8 10.3
Colorectal, % 4.3 5.6 0 1.5
HCC/CCC, % 3.4 3.9 3.8 1.5
Othera, % 16.9 16.8 19.2 16.2
Biopsy of adrenal metastasis % 5.2 5.8 7.4 2.5
Systemic therapy 4 weeks prior/after RT, % 16.9 17.7 18.5 13.9
Paused on RT days, % 10.4 8.1 0 21.5
Continued during RT, % 3.6 3.1 7.4 3.8
Drugs continued during RT or
only paused on RT days
Chemotherapy, % 19.6 20.7 0 20
Targeted therapy, % 29.4 24.1 100 30
Immunotherapy, % 47.1 51.7 0 45
Combination, % 3.9 3.4 0 5











Side Left/right, % 55.2/44.8 50/50 74.1/25.9 65.8/34.2
Primary tumor controlled at time of RT Yes/no, % 81.3/17.5 81/17.2 80.8/19.2 82.4/17.6
Unknown, % 1.2 1.7 0 0
Number of metastases at the time of RT
(including the adrenal lesion), %
1 (adrenal only) 32.8 36.2 19.2 26.5
2-3 23.0 24.1 23.1 19.1
4-5 10.1 6.9 11.5 20.6
>5 24.5 22.0 26.9 32.4
Unknown 9.5 10.8 19.2 1.5
Number of organ sites with metastases at
the
time of RT (including the adrenal site), %
1 (adrenal only) 33.1 36.6 19.2 26.5
2-3 43.3 41.8 53.8 44.1
4-5 11.7 9.5 7.7 20.6
>5 2.8 1.3 0 8.8
Unknown 9.2 10.8 19.2 0
Adrenal metastasis symptomatic? Yes/no 7.1/89.3 4.3/91.8 15.4/73.1 13.2/86.8
Unknown 3.7 3.9 11.5 0
Abbreviations: 3DCRT/IMRT, highly conformal RT with >12 fractions and a BED10 ≥50 Gy; CCC, cholangiocellular carcinoma; HCC, hepatocellular
carcinoma; KPS, Karnofsky performance status; NSCLC, non-small-cell lung cancer; Pall-RT, palliative radiotherapy with a BED10 ≤50 Gy; RT,
radiotherapy; SBRT, stereotactic body radiotherapy using ≤12 fractions and a BED10 of ≥50 Gy; SCLC, small-cell lung cancer.
aOther tumors include breast cancer, renal cell carcinoma, prostate carcinoma, sarcoma, gastric cancer, malignant thymoma, Merkel cell carcinoma, urethral
carcinoma, ovarian cancer, thyroid carcinoma, squamous cell skin cancer, cancer of unknown primary, esophageal carcinoma and anaplastic extramedullary
plasmacytoma.
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Karnofsky performance status (KPS) was 90% (range, 50%-100%) with
no clinically relevant or statistically significant differences between
the three groups (Table 1).
Biopsies of the adrenal lesions had been performed in 5.2%; sys-
temic therapy had been administered prior to RT in 30.9% of patients,
consisting of 16.9% with a pause of more than 4 weeks prior and after
RT, 10.4% with a shorter break and 3.6% with concurrent treatment
on RT days. In cases with no treatment interruption or only short
interruptions, most patients had received immunotherapy (47.1%;
mostly immune checkpoint inhibitors; one patient had received
interleukin-2), followed by targeted agents (29.4%), chemotherapy
(19.6%) and combinations (3.9%).
Irradiated lesions were more often right-sided in the SBRT group
compared to both other groups (both P < .05). Side distribution did
not differ significantly between the 3DCRT/IMRT group and the Pall-
RT group. Bilateral RT was performed in 40 patients out of whom
28, 1 and 11 were in the SBRT, 3DCRT/IMRT and Pall-RT groups,
respectively.
At the time of RT, the primary tumor was controlled in 81.3% of
patients. The treated adrenal metastasis was the only metastatic site
in 32.8% of the patients, 23.0% of patients had an oligometastatic sit-
uation with 2 to 3 lesions, 10.1% of patients had four to five lesions in
total and 24.5% of patients had more than five lesions (9.5%
unknown). Patients who had received SBRT were more likely to have
no other metastatic lesions in total compared to the other strata com-
bined (P = .032; Table 1).
Lesions were more often symptomatic in the Pall-RT group and in
the 3DCRT/IMRT group compared to the SBRT group (both P < .05;
Table 1).
The median time interval between the diagnosis of the adrenal
metastasis and the initiation of RT was 3.5 months (mean: 7.7 months),
without relevant or significant differences between the three sub-
groups. Imaging prior to RT was performed with computed tomography
(CT) or positron emission tomography CT scans in most cases (Table 2).
Immobilization for RT positioning was performed using a vacuum
mold, a breast board or a wing step breast board in 54.9%, 21.3% and
5.5% of lesions, respectively. Multiple techniques were used in 14.8%
of patients (unknown in 0.5%; no immobilization was used in 3% of
lesions). Daily IGRT was mostly performed using cone-beam CT
(77.3%) followed by stereoscopic kilovoltage imaging (16.1%), and
megavoltage fan-beam CT (3%); all other modalities taken together
were used in 3.3% of patients (unknown in 0.3%). Any kind of motion
management was applied in 59.8% of patients (unknown: 9.6%; free-
breathing in 30.6%). If motion management was applied, abdominal
compression was preferred (24.9%), followed by breath-hold tech-
niques (22.7%), gating (10.4%) and tracking (1.9%; Table 2).
The mean gross tumor volume (GTV) size was 49.8 mL (median:
24.8 mL) resulting in an average planning target volume (PTV) size of
103.7 mL (median: 64.6 mL) with safety margins depending on institu-
tional protocols (quartiles and parameters for each group are shown in
Table 2). The GTV size was smaller in the SBRT group compared to
the other groups combined (P < .05 for SBRT vs 3DCRT/IMRT and
Pall-RT; there were no further significant between-group differences).
The most common fractionation schedules were 50 Gy in 10 frac-
tions (19.7%), 25 Gy in 5 fractions (7.7%), 35 Gy in 5 fractions (7.4%)
and 40 Gy in 5 fractions (6.6%); multiple other dosing regimens were
used in the rest of patients (58.7%; see Table 2 for subgroups).
The mean prescription BED10 to the PTV was 64.2 Gy
(±18.9 Gy); the mean PTV-D98 (BED10) was 59.8 Gy (±20 Gy), the
mean PTV-D50 was 76.3 Gy (±29.7 Gy). The mean PTV-D2 was
88 Gy (±37.4 Gy) and the average GTV dose (GTVmean, BED10) was
81.4 Gy (±34.2 Gy).
3.2 | Local control
The median unadjusted FFLP for all patients was 39.7 months. The
proportions of patients who were free from local recurrence after
12 months for SBRT, 3DCRT/IMRT and Pall-RT were 80.8%, 60.6%
and 57.7%, respectively (Supplementary Figure S1); after SBRT, FFLP
was significantly higher compared to Pall-RT (P = .026). No statistically
significant difference in FFLP was observed after 3DCRT/IMRT com-
pared to SBRT or after 3DCRT/IMRT compared to Pall-RT
(both P > .05).
CRA-LRR was numerically higher after Pall-RT but the difference
was not statistically significant in the adjusted model (P = .140 for
SBRT vs Pall-RT); additionally, there was no significant difference
between the other groups (both comparisons: P > .05). Numerically,
the 12-months rate of local recurrences for the whole cohort was
17.7%. In the subgroups, CRA-LRR was 13.8%, 17.4% and 27.7% after
SBRT, 3DCRT/IMRT and Pall-RT, respectively (Figure 1A). After
24 months, the CRA-LRR was 27.0% for the overall dataset and
24.5%, 21.7% and 35.9% after SBRT, 3DCRT/IMRT and Pall-RT,
respectively. Further details on deaths without local recurrences and
confidence intervals of the cumulative incidence model are shown in a
multiple panel analysis in Figure 1B for each stratum.
3.3 | Progression-free survival
The median PFS after SBRT, 3DCRT/IMRT and Pall-RT was 5.9, 4.1
and 3.7 months, respectively. After 12 months, the PFS rate was
30.9%, 24.3% and 16.5% after SBRT, 3DCRT/IMRT and Pall-RT,
respectively, the 24-months values were 16.1%, 19.5% and 5.9%
(Figure 2).
The SBRT group had a significantly longer PFS compared to the
Pall-RT group (P = .0019). There was no significant difference
between the 3DCRT/IMRT group and the Pall-RT group; furthermore,
there was no significant difference in PFS between the SBRT group
and the 3DCRT/IMRT group (both P > .05).
3.4 | Overall survival
The median OS rates after SBRT, 3DCRT/IMRT and Pall-RT were
19.1, 5.7 and 17.1 months; the 12-month OS rates were 67.1%,









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Group: 3DCRT/IMRT Pall−RT SBRT
Cumulative incidence of local recurrence. 
Comparison of 3DCRT/IMRT vs Pall−RT vs SBRT.
23 5 3 1 1 0
71 24 8 4 2 2







F IGURE 1 A, Cumulative incidence function of local recurrences corrected for competitive events (not shown). 3DCRT/IMRT (blue), Pall-RT (red)
and SBRT (green). The differences between the groups were not significant (Gray's test; all P > .05). Interestingly, the Kaplan-Meier model which is not
corrected for competitive events showed a significant difference between the SBRT group and the Pall-RT group (Log-rank, P = .026; Supplementary
Figure S1). B, Cumulative incidence function as described in A; however, this figure includes curves for competitive events, depicts the groups in
multiple panels (A-C) and shows the 95% confidence intervals; the comparison of competitive events between the groups showed that in the 3DCRT/
IMRT group, deaths without local recurrences occurred significantly more frequently compared to the SBRT group (Gray's test; P = .027) [Color figure
can be viewed at wileyonlinelibrary.com]
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Progression−free survival by treatment group (3DCRT/IMRT, Pall−RT, SBRT)
23 5 4 2 2 0
62 7 2 1 0 0





Strata | | |3DCRT/IMRT Pall−RT SBRT
F IGURE 2 This figure shows progression-free survival (PFS) curves for 3DCRT/IMRT (blue), Pall-RT (red) and SBRT (green); differences were
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Overall survival by treatment group (3DCRT/IMRT, Pall−RT, SBRT)
26 9 7 3 2 1
68 36 10 6 2 2





Strata | | |3DCRT/IMRT Pall−RT SBRT
F IGURE 3 Overall survival (OS) curves for 3DCRT/IMRT (blue), Pall-RT (red) and SBRT (green) are shown in this figure. Differences between
groups are significant for the comparison of SBRT vs Pall-RT (P = .041) and also for the comparison of SBRT vs 3DCRT/IMRT (P = .0028) but not
for the difference of 3DCRT/IMRT vs Pall-RT. Details on direct comparisons between the groups are shown in Supplementary Figures S2-S4
[Color figure can be viewed at wileyonlinelibrary.com]
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34.6% and 62.5%, and the 24-month OS rates were 45.6%, 26.9%
and 27.0% for SBRT, 3DCRT/IMRT and Pall-RT, respectively
(Figure 3). Differences between groups were significant for the com-
parison of SBRT v. Pall-RT (P = .041; Supplementary Figure S2) and
for SBRT v. 3DCRT/IMRT (P = .0028; Supplementary Figure S3); no
significant difference was observed between the 3DCRT/IMRT group
and the Pall-RT group (Supplementary Figure S4).
3.5 | Univariate associations of other factors with
FFLP and survival
We did not observe a difference between right-sided or left-
sided lesions in terms of FFLP or OS (both P > .05). Patients who
had no other metastases aside from the adrenal lesion showed a
longer OS and a longer PFS compared to patients with more
metastases (both P < .05). Data on local treatment of metastases
other than the adrenal lesion were not available; however,
patients with ≤3 lesions in total (including the treated lesion)
showed no significant difference in terms of OS but there was an
improved PFS compared to the other patients; the same was true
for patients who had only up to three organs affected by
metastases (irrespective of the number of metastases in each
organ). Patients with ≤5 lesions did not show an improvement in
OS or PFS compared to those with more lesions; again, patients
with up to five affected organ systems did not show an OS or
PFS benefit compared to patients with more organ systems
affected at the time of RT. Patients with symptomatic adrenal
metastases had a worse OS compared to asymptomatic patients
(P = .007; median: 18.3 vs 9.9 months).
Finally, a landmark analysis was performed at 12 months to com-
pare OS outcomes of patients who were alive at 12 months with or
without local recurrence. Patients with a locally controlled adrenal
metastasis at 12 months had a significantly longer OS compared to
patients whose adrenal metastasis was not locally controlled at
12 months (P < .0001; median OS: 78.1 vs 19.1 months; see Figure 4).
3.6 | Specific toxicity—adrenal insufficiency
Four cases with adrenal insufficiency occurred out of which two were
observed in patients after unilateral treatment and two were observed
after bilateral treatment. A case-by-case analysis was performed for
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Landmark analysis at 12 months
107 107 57 23 13 7
33 33 7 2 0 0Recurred
No local
recurrence
0 12 24 36 48 60
Number at risk
Strata | |No localrecurrence Recurred
F IGURE 4 This figure shows a landmark analysis of the whole patient cohort for the comparison of patients who developed a local
recurrence during the first year of follow-up vs patients who were alive at 1 year but remained locally controlled. The difference between the
curves was significant (P < .0001), indicating that in our cohort, occurrence of a local recurrence during the first year of follow-up was associated
with a worse OS. Patients with bilateral lesions were included in this analysis using the first lesion which was mentioned by the referring center as
a reference lesion and censoring the contralateral site; the analysis was repeated after exclusion of all patients with bilateral lesions with similar
results and similar between-group differences (P < .0001) [Color figure can be viewed at wileyonlinelibrary.com]
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therapy due to late-onset adrenal insufficiency 10 months after bilat-
eral RT; he was in the Pall-RT group and had received moderate RT
doses to both adrenal glands (25 Gy in five fractions; PTV-D2(BED10)
was 48.7 and 49.5 Gy for right- and left-sided RT, respectively). The
second patient with adrenal insufficiency after bilateral RT experi-
enced acute onset of symptoms. He had received RT with a PTV-D2
(BED10), right and left: 116.4 and 101.6 Gy, respectively; he required
hormone substitution until death 10 months after RT (unknown rea-
son; however, diffuse distant progression had occurred 1 month
post-RT.
Two further cases were noted after unilateral RT; both hap-
pened in conjunction with systemic therapy: The first patient had a
PTV-D2(BED10) of 38.1 Gy concurrently with interleukin-2 for
metastatic melanoma. A mild adrenal insufficiency occurred
1 month after RT; it is unclear if this was primarily caused by one-
sided RT, or happened as a side effect of interleukin-2 40 or if an
immune response was triggered by the combination of RT and
immune therapy.
The second patient with an adrenal insufficiency after unilat-
eral RT had received nivolumab due to metastatic kidney cancer.
Nivolumab had to be stopped 2 months prior to RT due to
immune-related colitis (Grade 3) which was treated with cortico-
steroids; tumor treatment was switched to cabozantinib (adminis-
tered continuously during RT). Although bilateral adrenal
metastases were present, only the right side was planned for
treatment with a PTV-D2(BED10) of 77.9 Gy. Shortly after treat-
ment was initiated acute kidney injury (AKI) and hormone dys-
function were diagnosed, presumably caused by discontinuation
of corticosteroids prior to symptom onset. The patient was
readmitted 10 days after completion of RT with another episode
of AKI and Addison's crisis; he died 1 month later due to pneumo-
nia, ascites, AKI and sepsis. Although an RT-related toxicity can-
not be ruled out, the likelihood of an immunotherapy-related side
effect41 and/or a tumor-triggered deterioration was deemed more
likely.
3.7 | Acute and chronic gastrointestinal and other
toxicity
Acute gastrointestinal toxicity (≥2 or in need of therapy) occurred in
a range of 2 to 53 days post-RT and was rare: nausea and vomiting
requiring antiemetic therapy, but no hospital admission, occurred in
4.6% (n = 15) of patients. One case with a duodenal stenosis and pain
(Grade 3) was observed; the patient had tumor infiltration of the ret-
roperitoneal plexus and onset of symptoms was only 1 month after
SBRT; therefore, tumor-related symptoms were deemed more likely
although RT-related toxicity could not be ruled out. Fatigue was
observed in 9.8% of patients. Electrolyte imbalances in patients with-
out proven adrenal insufficiency were rare (<1%; n = 1 hyperkalemia,
n = 1 hyponatremic dehydration).
One gastric ulceration occurred 6 months after RT in a patient
who had received a Dmax of 31 Gy in 5 fractions to the stomach;
other than that, no Grade 2 late gastrointestinal toxicity was reported.
Flank pain occurred in <1% of the patients. No other (eg, hepatic,
renal or skin) toxicities were reported.
4 | DISCUSSION
To the best of our knowledge, this is the largest retrospective multi-
center study on the radiotherapeutic treatment of adrenal metastases
which has been conducted to date. This patterns-of-care analysis
showed a wide range of fractionation schedules for RT treatment of
adrenal metastases. Most patients were treated with SBRT which
required a BED10 of at least 50 Gy in 12 fractions or less.9 Patients
with symptomatic lesions and patients with larger lesions were prefer-
entially treated with lower “palliative” doses (Pall-RT group) or with
more than 12 fractions (3DCRT/IMRT group); likewise, patients who
were treated with SBRT were more likely to have a solitary or a right-
sided lesion. Taken together, baseline factors indicated an imbalance
between the SBRT stratum compared to 3DCRT/IMRT- and Pall-RT
strata with SBRT patients having a more favorable risk profile. Fur-
thermore, there was a lack of standardization which is most likely
explained by the very limited evidence about best-practice radiother-
apy for adrenal metastases and strongly indicates the need for
increased efforts into retrospective and especially prospective
studies.
The risk of death without local recurrence was also unevenly dis-
tributed between the arms with an increased risk after 3DCRT/IMRT
compared to SBRT. In all strata, the risk of death without local recur-
rence was numerically more frequent than local recurrence events;
therefore, the unadjusted (Kaplan-Meier) LC estimate in this setting
was considered inaccurate.36,37 Despite this assumption, we decided
to report on both the adjusted and the unadjusted numbers. This was
done to facilitate comparability with other studies which mostly used
unadjusted values.30,34,42
The unadjusted LC differed between the arms and was in line
with the two other larger datasets: after prescribed doses of
100, 80 and 60 Gy (BED10), Chen et al32 found in their meta-analysis
1-year LC rates of 92.9%, 84.8% and 70.5%; Zhao et al34 calculated
an unadjusted 1-year LC estimate of 83.8% after an average BED10
of 79.6 Gy. In our cohort, the unadjusted 1-year FFLP-estimates were
80.8%, 60.6% and 57.7%, after average prescribed BED10 doses of
72.0 Gy (SBRT), 58.9 Gy (3DCRT/IMRT) and 40.4 Gy (Pall-RT),
respectively. As expected, the adjusted recurrence rates were consid-
erably higher with CRA-LRR of 13.8%, 17.4% and 27.7% in the SBRT,
3DCRT/IMRT and Pall-RT groups, respectively. The lack of statistical
significance may be explained by several factors: despite the size of
the overall cohort, patient numbers in the subgroups of Pall-RT and
3DCRT/IMRT were limited and statistical differences in FFLP might
have been obscured by differences in histology, lesion size and sys-
temic treatments. Furthermore, the minimum BED10 in the SBRT
group was 50 Gy, a dose which is well below the BED10 of 100 Gy
which is typically considered ablative, for example, in lung cancer
which was the largest subgroup.43
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Although there was a numerical difference between the groups,
differences in CRA-LRR did not reach statistical significance. This may
be explained by confounders such as distribution of radiosensitive
tumors or our dataset might have been underpowered; finally, our
cutoff values to define SBRT and/or 3DCRT/IMRT may be lower than
the dose that is required to achieve durable tumor control. Dosimetric
analyses of the dataset are ongoing with preliminary results indicating
that dose escalation was associated with LC in this cohort albeit at
higher cutoff values.
Additionally, dose coverage and prescription patterns differed
between centers. More detailed subgroup analyzes about the impact
of prescription patterns, dose coverage and higher dose escalation in
the SBRT group are ongoing.
PFS data in our study showed improved outcomes after SBRT
compared to Pall-RT; OS was also longer after SBRT compared to
both other groups; it is likely that both observations were partially
explained by aforementioned imbalances. We observed a strong asso-
ciation between FFLP at 12 months and OS in a landmark analysis,
indicating that long-term FFLP was also associated with
OS. Furthermore, improved OS and PFS outcomes were observed in
patients who had only one lesion (or one affected organ) compared to
those with more metastatic lesions or sites. Patients with ≤3 lesions
had an improved PFS compared to other patients but not an improved
OS. However, we did not observe better outcomes in patients with
≤5 lesions compared to patients with multiple metastases. Unfortu-
nately, our analysis on oligometastatic patients does not yet include
treatment data on lesions other than the adrenal sites; therefore, the
informative value of the comparisons is limited. As shown by the land-
mark analysis, patients who were free from local recurrences and alive
after 1 year had a longer OS compared to patients who were alive but
not free from local failures. This indicates that LC might be associated
with OS in this setting; however, such an analysis cannot distinguish
between treatment effects or effects caused by confounding factors.
Most recently, data from the long-term analysis of the SABR-COMET
Phase II trial were published. The results suggest that SBRT for
oligometastatic solid tumors might not only result in an improved PFS
but is also associated with an OS benefit.44
In our study, gastrointestinal toxicities were mild and rare. Adre-
nal insufficiency was rare; however, occurred after relatively low
doses (25 Gy in five fractions). Cutoff doses could not be determined
due to the limited number of patients at risk. As indicated by surgical
series, adrenal function might recover if 15% to 30% of healthy tissue
is left after adrenalectomy.45 Nevertheless, even unilateral adrenalec-
tomy was associated with adrenal insufficiency in 22% of cases.46 The
risk of adrenal insufficiency after unilateral treatment in our study was
low and possibly associated with concomitant medication. Neverthe-
less, considering the results of surgical series and our data, all patients
should be informed about the risk of adrenal insufficiency and labora-
tory screening should be performed during follow-up.46
To sum up, both unilateral and bilateral RT of the adrenal glands
is associated with acceptable rates of adrenal insufficiency, especially
considering that untreated bilateral adrenal metastases are also asso-
ciated with a 3% to 8% risk of adrenal insufficiency.47
Major limitations of our study are the retrospective approach and
the inhomogeneity of the cohort in terms of RT approaches and tumors.
5 | CONCLUSION
Adrenal RT was associated with an acceptable FFLP in all arms and a
favorable FFLP after SBRT. Aside from sporadic cases of adrenal
insufficiency, toxicity was generally mild. Follow-up visits should
include monitoring for adrenal insufficiency and patients should be
informed about the potential risk. Solitary adrenal metastases and
1-year FFLP were associated with a longer OS. Dose-response ana-
lyses for the dataset are underway.
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